Video

Will Biosimilars Reduce Specialty Drug Spending?

Author(s):

Davy James, Managing Editor

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Image credit: adragan | stock.adobe.com
Related Content
Adalimumab (Humira) biosimilar (Hyrimoz) -- Image credit: luchschenF | stock.adobe.com
August 29th 2025

Switching From Reference Adalimumab to Biosimilar Shows No Major Differences in Patients With RA, PsA

Gillian McGovern, Associate Editor
Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage
August 29th 2025

Pharmacy Focus: Role of Pharmacists in Proper Inhaler Usage

Jennifer Griffin, PharmD, MS Luke Halpern, Assistant Editor
Denosumab (Xgeva) -- Image credit: Tenacity_1987 | stock.adobe.com
August 29th 2025

LY01011, Biosimilar of Denosumab, Meets Primary End Point in Study

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
August 29th 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Op-Ed: Why Banning PBM-Owned Pharmacies Risks Patient Care
August 29th 2025

Op-Ed: Why Banning PBM-Owned Pharmacies Risks Patient Care

Ben Heiser, PharmD
GLP-1 dulaglutide (Trulicity) -- Image credit: Edugrafo | stock.adobe.com
August 29th 2025

Dulaglutide Biosimilar Achieves Equivalent Efficacy in HbA1c Reduction in Patients With T2DM

Gillian McGovern, Associate Editor